Last reviewed · How we verify
hydration plus rosuvastatin therapy
Hydration plus rosuvastatin therapy combines fluid replacement with HMG-CoA reductase inhibition to improve hydration status and reduce cholesterol synthesis.
Hydration plus rosuvastatin therapy combines fluid replacement with HMG-CoA reductase inhibition to improve hydration status and reduce cholesterol synthesis. Used for Hypercholesterolemia and dyslipidemia management in hospitalized patients requiring fluid resuscitation.
At a glance
| Generic name | hydration plus rosuvastatin therapy |
|---|---|
| Sponsor | Shenyang Northern Hospital |
| Drug class | Statin (HMG-CoA reductase inhibitor) |
| Target | HMG-CoA reductase |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Rosuvastatin is a statin that inhibits HMG-CoA reductase, the rate-limiting enzyme in cholesterol biosynthesis, thereby lowering LDL cholesterol and triglycerides. The addition of hydration therapy aims to optimize fluid balance and potentially improve drug efficacy and tolerability, particularly in hospitalized or acute care settings.
Approved indications
- Hypercholesterolemia and dyslipidemia management in hospitalized patients requiring fluid resuscitation
Common side effects
- Myalgia
- Elevated liver enzymes
- Headache
- Nausea
Key clinical trials
- Evaluation of the Effect of Rosuvastatin on Cisplatin-induced Nephrotoxicity and Ototoxicity (PHASE2)
- A Randomized Trial of Rosuvastatin Loading Combined With Early hydrAtion Versus Standard-of-care Medications for the Prevention of CIAKI in Patient With AMI Undergoing Emergency PCI (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |